Cargando…
Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation
In the Wuhan province of China, almost two years ago, in December 2019, the novel Coronavirus 2019 has caused a severe involvement of the lower respiratory tract leading to an acute life-threatening respiratory syndrome, coronavirus disease-19 (COVID-19). Subsequently, coronavirus 2 (SARS-CoV-2) rap...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Scientific and Technological Research Council of Turkey
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771052/ https://www.ncbi.nlm.nih.gov/pubmed/34844296 http://dx.doi.org/10.3906/sag-2110-179 |
_version_ | 1784635512113332224 |
---|---|
author | TUFAN, Abdurrahman MATUCCI CERINIC, Marco |
author_facet | TUFAN, Abdurrahman MATUCCI CERINIC, Marco |
author_sort | TUFAN, Abdurrahman |
collection | PubMed |
description | In the Wuhan province of China, almost two years ago, in December 2019, the novel Coronavirus 2019 has caused a severe involvement of the lower respiratory tract leading to an acute life-threatening respiratory syndrome, coronavirus disease-19 (COVID-19). Subsequently, coronavirus 2 (SARS-CoV-2) rapidly spread to the entire world causing a pandemic and affected every single person on earth either directly or indirectly with destroying all facets of social life and economy. Since the announcement of COVID-19 as a global pandemic, we have witnessed tremendous scientific work on all aspects of COVID-19 across the globe, which has never been witnessed before. The most remarkable achievement would be the introduction of vaccines, which provide protection from the severe infection and is the only premise for the control of disease. However, despite the tremendous work, the number of treatments either antiviral or immunomodulatory for infected patients are considerably limited, yet disease is causing substantial morbidity and mortality. COVID-19 follows heterogenous disease course among infected individuals, and dysregulated immune system is primarily responsible for the worse outcomes. Immune deficiency, being on corticosteroids for inflammatory diseases, delayed interferon response and advanced age adversely influence prognosis with impairing viral clearance. On the other hand, exuberant immune response with features of cytokine storm is the leading cause of death, which can be alleviated by use of either general immunosuppression with corticosteroids or selective neutralization of potent pro-inflammatory cytokines such as interleukin (IL)-1 and IL-6. Herein, we summarized the potential effective immunomodulatory treatments emphasizing in which patient population it is the most suitable, which dose should be administered, and which is the most appropriate timepoint to administer the drug during the course of the disease. |
format | Online Article Text |
id | pubmed-8771052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Scientific and Technological Research Council of Turkey |
record_format | MEDLINE/PubMed |
spelling | pubmed-87710522022-02-01 Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation TUFAN, Abdurrahman MATUCCI CERINIC, Marco Turk J Med Sci Article In the Wuhan province of China, almost two years ago, in December 2019, the novel Coronavirus 2019 has caused a severe involvement of the lower respiratory tract leading to an acute life-threatening respiratory syndrome, coronavirus disease-19 (COVID-19). Subsequently, coronavirus 2 (SARS-CoV-2) rapidly spread to the entire world causing a pandemic and affected every single person on earth either directly or indirectly with destroying all facets of social life and economy. Since the announcement of COVID-19 as a global pandemic, we have witnessed tremendous scientific work on all aspects of COVID-19 across the globe, which has never been witnessed before. The most remarkable achievement would be the introduction of vaccines, which provide protection from the severe infection and is the only premise for the control of disease. However, despite the tremendous work, the number of treatments either antiviral or immunomodulatory for infected patients are considerably limited, yet disease is causing substantial morbidity and mortality. COVID-19 follows heterogenous disease course among infected individuals, and dysregulated immune system is primarily responsible for the worse outcomes. Immune deficiency, being on corticosteroids for inflammatory diseases, delayed interferon response and advanced age adversely influence prognosis with impairing viral clearance. On the other hand, exuberant immune response with features of cytokine storm is the leading cause of death, which can be alleviated by use of either general immunosuppression with corticosteroids or selective neutralization of potent pro-inflammatory cytokines such as interleukin (IL)-1 and IL-6. Herein, we summarized the potential effective immunomodulatory treatments emphasizing in which patient population it is the most suitable, which dose should be administered, and which is the most appropriate timepoint to administer the drug during the course of the disease. The Scientific and Technological Research Council of Turkey 2021-12-17 /pmc/articles/PMC8771052/ /pubmed/34844296 http://dx.doi.org/10.3906/sag-2110-179 Text en Copyright © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Article TUFAN, Abdurrahman MATUCCI CERINIC, Marco Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation |
title | Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation |
title_full | Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation |
title_fullStr | Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation |
title_full_unstemmed | Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation |
title_short | Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation |
title_sort | immune dysfunction in covid-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771052/ https://www.ncbi.nlm.nih.gov/pubmed/34844296 http://dx.doi.org/10.3906/sag-2110-179 |
work_keys_str_mv | AT tufanabdurrahman immunedysfunctionincovid19andjudicioususeofantirheumaticdrugsforthetreatmentofhyperinflammation AT matuccicerinicmarco immunedysfunctionincovid19andjudicioususeofantirheumaticdrugsforthetreatmentofhyperinflammation |